Compare Stocks: GBIO, HURA, MIST, and UNCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBIO Generation Bio	$5.34	$5.48	$3.00 ▼ $6.95	$35.99M	2.05	160,744 shs	N/A
HURA TuHURA Biosciences	$2.15 -0.9%	$2.29	$0.41 ▼ $3.90	$136.91M	-0.01	1.13 million shs	132,042 shs
MIST Milestone Pharmaceuticals	$1.10 -1.4%	$1.27	$1.00 ▼ $3.06	$136.33M	0.97	1.90 million shs	556,769 shs
UNCY Unicycive Therapeutics	$5.07 +1.1%	$6.36	$3.71 ▼ $8.74	$138.98M	1.79	956,956 shs	370,688 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBIO Generation Bio	0.00%	0.00%	0.00%	0.00%	+26.84%
HURA TuHURA Biosciences	0.00%	+2.84%	-11.07%	-6.87%	-9.58%
MIST Milestone Pharmaceuticals	0.00%	-4.31%	-15.91%	-40.64%	-22.38%
UNCY Unicycive Therapeutics	0.00%	-7.22%	-12.57%	-34.68%	+19.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBIO Generation Bio	$5.34	$5.48	$3.00 ▼ $6.95	$35.99M	2.05	160,744 shs	N/A
HURA TuHURA Biosciences	$2.15 -0.9%	$2.29	$0.41 ▼ $3.90	$136.91M	-0.01	1.13 million shs	132,042 shs
MIST Milestone Pharmaceuticals	$1.10 -1.4%	$1.27	$1.00 ▼ $3.06	$136.33M	0.97	1.90 million shs	556,769 shs
UNCY Unicycive Therapeutics	$5.07 +1.1%	$6.36	$3.71 ▼ $8.74	$138.98M	1.79	956,956 shs	370,688 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBIO Generation Bio	0.00%	0.00%	0.00%	0.00%	+26.84%
HURA TuHURA Biosciences	0.00%	+2.84%	-11.07%	-6.87%	-9.58%
MIST Milestone Pharmaceuticals	0.00%	-4.31%	-15.91%	-40.64%	-22.38%
UNCY Unicycive Therapeutics	0.00%	-7.22%	-12.57%	-34.68%	+19.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GBIO Generation Bio	2.29	Hold	$8.88	66.20% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	318.60% Upside
MIST Milestone Pharmaceuticals	2.67	Moderate Buy	$7.25	562.10% Upside
UNCY Unicycive Therapeutics	2.43	Hold	$21.75	329.33% Upside

Current Analyst Ratings Breakdown

Latest GBIO, HURA, MIST, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/17/2026	HURA TuHURA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	MIST Milestone Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	MIST Milestone Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/1/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Speculative Buy	$18.00 ➝ $13.00
6/30/2026	UNCY Unicycive Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00
6/30/2026	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$22.00 ➝ $15.00
6/9/2026	UNCY Unicycive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/2/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy	$15.00 ➝ $18.00
5/27/2026	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00
5/15/2026	MIST Milestone Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GBIO Generation Bio	$19.89M	1.81	N/A	N/A	$12.91 per share	0.41
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
MIST Milestone Pharmaceuticals	$1.78M	76.42	N/A	N/A	$0.39 per share	2.81
UNCY Unicycive Therapeutics	$680K	204.06	N/A	N/A	$1.41 per share	3.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GBIO Generation Bio	-$131.67M	-$9.34	N/A	N/A	N/A	-410.13%	-94.82%	-34.13%	N/A
HURA TuHURA Biosciences	-$30.05M	-$0.61	N/A	N/A	N/A	N/A	-156.12%	-105.38%	8/13/2026 (Estimated)
MIST Milestone Pharmaceuticals	-$63.06M	-$0.68	N/A	N/A	N/A	N/A	-339.33%	-61.79%	8/12/2026 (Estimated)
UNCY Unicycive Therapeutics	-$26.56M	-$2.21	N/A	0.65	N/A	N/A	-134.69%	-84.51%	8/13/2026 (Estimated)

Latest GBIO, HURA, MIST, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	UNCY Unicycive Therapeutics	-$0.4710	N/A	N/A	N/A	$22.22 million	N/A
8/12/2026	Q2 2026	MIST Milestone Pharmaceuticals	-$0.18	N/A	N/A	N/A	$0.82 million	N/A
5/15/2026	Q1 2026	HURA TuHURA Biosciences	-$0.12	-$0.13	-$0.01	-$0.13	N/A	N/A
5/13/2026	Q1 2026	MIST Milestone Pharmaceuticals	$0.06	-$0.20	-$0.26	-$0.20	$30.12 million	$0.24 million
5/12/2026	Q1 2026	UNCY Unicycive Therapeutics	-$0.4589	-$0.54	-$0.0811	-$0.54	$11.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GBIO Generation Bio	N/A	4.44	4.44
HURA TuHURA Biosciences	N/A	1.15	1.15
MIST Milestone Pharmaceuticals	1.61	9.18	9.09
UNCY Unicycive Therapeutics	N/A	2.40	2.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GBIO Generation Bio	95.22%
HURA TuHURA Biosciences	0.62%
MIST Milestone Pharmaceuticals	86.18%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
GBIO Generation Bio	21.10%
HURA TuHURA Biosciences	6.06%
MIST Milestone Pharmaceuticals	5.03%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GBIO Generation Bio	150	6.74 million	5.32 million	Optionable
HURA TuHURA Biosciences	N/A	63.68 million	59.82 million	N/A
MIST Milestone Pharmaceuticals	30	124.50 million	118.24 million	Optionable
UNCY Unicycive Therapeutics	9	27.39 million	25.74 million	Not Optionable

GBIO, HURA, MIST, and UNCY Headlines

Recent News About These Companies

Critical Comparison: Phio Pharmaceuticals (NASDAQ:PHIO) versus Unicycive Therapeutics (NASDAQ:UNCY)

July 27, 2026 | americanbankingnews.com

Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Strong Sell Rating by Zacks Research

July 23, 2026 | marketbeat.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 19, 2026 | marketbeat.com

Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group

July 16, 2026 | theglobeandmail.com

UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

July 13, 2026 | globenewswire.com

Guggenheim Remains a Buy on Unicycive Therapeutics (UNCY)

July 10, 2026 | theglobeandmail.com

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

July 10, 2026 | globenewswire.com

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

July 8, 2026 | businesswire.com

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...

July 8, 2026 | tmcnet.com

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

July 8, 2026 | businesswire.com

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced - Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

July 8, 2026 | tmcnet.com

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

July 7, 2026 | businesswire.com

UNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

July 6, 2026 | globenewswire.com

Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

July 6, 2026 | newsfilecorp.comN

Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm

July 2, 2026 | globenewswire.com

Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies

July 2, 2026 | finance.yahoo.com

UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

July 1, 2026 | businesswire.com

UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Encouraged to Contact the Firm

July 1, 2026 | globenewswire.com

US FDA declines to approve Unicycive's kidney disease drug

June 30, 2026 | reuters.com

UNCY stock crashed 45% today – why did FDA reject its kidney disease NDA for a second time?

June 30, 2026 | msn.com

Unicycive shares plunge after FDA issues complete response letter for kidney disease drug (UNCY)

June 30, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, HURA, MIST, and UNCY Company Descriptions

Generation Bio NASDAQ:GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

TuHURA Biosciences NASDAQ:HURA

$2.15 -0.02 (-0.92%)

As of 02:43 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Milestone Pharmaceuticals NASDAQ:MIST

$1.10 -0.02 (-1.35%)

As of 02:43 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Unicycive Therapeutics NASDAQ:UNCY

$5.07 +0.06 (+1.12%)

As of 02:44 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GBIO, HURA, MIST, and UNCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GBIO, HURA, MIST, and UNCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GBIO, HURA, MIST, and UNCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, HURA, MIST, and UNCY Company Descriptions

Generation Bio NASDAQ:GBIO

TuHURA Biosciences NASDAQ:HURA

Milestone Pharmaceuticals NASDAQ:MIST

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GBIO, HURA, MIST, and UNCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GBIO, HURA, MIST, and UNCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GBIO, HURA, MIST, and UNCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, HURA, MIST, and UNCY Company Descriptions

Generation Bio NASDAQ:GBIO

TuHURA Biosciences NASDAQ:HURA

Milestone Pharmaceuticals NASDAQ:MIST

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools